Skip to content

Evidence

Topics: Breast
Chest
Prostate Clear filters
conference presentation

206 Screening Benefits and Harms; A Review of False Positives and Negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) Programme

BTOG: Poster Presentation
Palmer et al. 2025

 

Clinical outcomes from the SWAG TLHC programme were reviewed to better understand potential harms, including over-investigation, missed diagnoses and cancers developing between screening rounds. Of the scans reviewed, 4098/4198 (97.6%) were negative (confirmed true negatives) and 80/4198 (1.9%) were abnormal (confirmed true positives). One person was diagnosed with lung cancer 18 months after a reportedly normal TLC scan, giving a false negative rate of 0.02%.

Read more
Disclaimers: DeepHealth Prostate is manufactured as Quantib Prostate by Quantib BV for DeepHealth Inc., DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc., DeepHeath Lung Tracker is manufactured as Veye Clinic by Aidence BV for DeepHealth Inc. and DeepHealth Brain is manufactured as Quantib ND by Quantib BV for DeepHealth Inc. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact us